Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

被引:26
|
作者
Quenel-Tueux, Nathalie [1 ]
Debled, Marc [1 ]
Rudewicz, Justine [1 ,2 ,3 ,4 ,5 ]
MacGrogan, Gaetan [1 ,2 ,3 ]
Pulido, Marina [6 ,7 ]
Mauriac, Louis [1 ]
Dalenc, Florence [8 ]
Bachelot, Thomas [9 ]
Lortal, Barbara [1 ]
Breton-Callu, Christelle [1 ]
Madranges, Nicolas [1 ]
de lara, Christine Tunon [1 ]
Fournier, Marion [1 ]
Bonnefoi, Herve [1 ,2 ,3 ]
Soueidan, Hayssam [4 ]
Nikolski, Macha [3 ,4 ,5 ]
Gros, Audrey [1 ,2 ,3 ]
Daly, Catherine [10 ]
Wood, Henry [10 ]
Rabbitts, Pamela [10 ]
Iggo, Richard [1 ,2 ,3 ]
机构
[1] Inst Bergonie, Ctr Comprehens Canc, F-33000 Bordeaux, France
[2] INSERM, U916, F-33000 Bordeaux, France
[3] Univ Bordeaux, F-33608 Pessac, France
[4] Univ Bordeaux, Bordeaux Bioinformat Ctr, F-33076 Bordeaux, France
[5] CNRS, UMR5800, Bordeaux Comp Sci Lab, F-33405 Talence, France
[6] INSERM, Clin Invest Ctr, CIC1401, Epidemiol Unit, F-33076 Bordeaux, France
[7] Inst Bergonie, Clin & Epidemiol Res Unit, F-33076 Bordeaux, France
[8] Inst Claudius Regaud, IUCT Oncopole Toulouse, F-31059 Toulouse, France
[9] CLCC Lyon, F-69008 Lyon, France
[10] Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England
关键词
anastrozole; endocrine treatment; fulvestrant; hormone-receptor-positive cancer; large operable or locally advanced breast cancer; neo-adjuvant; NEOADJUVANT ENDOCRINE THERAPY; KI-67 LABELING INDEX; DOUBLE-BLIND; TAMOXIFEN; WOMEN; LETROZOLE; CHEMOTHERAPY; KI67;
D O I
10.1038/bjc.2015.247
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to identify genomic changes occurring after treatment. Methods: One hundred and twenty post-menopausal patients were randomised to receive 1mg anastrozole (61 patients) or 500mg fulvestrant (59 patients) for 6 months. Genomic DNA copy number profiles were generated for a subgroup of 20 patients before and after treatment. Results: A total of 108 patients were evaluable for efficacy and 118 for toxicity. The objective response rate determined by clinical palpation was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 53.8% (95% CI = 39.5-67.8) in the fulvestrant arm. The breast-conserving surgery rate was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 50.0% (95% CI = 35.8-64.2) in the fulvestrant arm. Pathological responses >50% occurred in 24 patients (42.9%) in the anastrozole arm and 13 (25.0%) in the fulvestrant arm. The Ki-67 score fell after treatment but there was no significant difference between the reduction in the two arms (anastrozole 16.7% (95% CI = 13.3-21.0) before, 3.2% (95% CI = 1.9-5.5) after, n = 43; fulvestrant 17.1% (95% CI = 13.1-22.5) before, 3.2% (95% CI = 1.8-5.7) after, n = 38) or between the reduction in Ki-67 in clinical responders and non-responders. Genomic analysis appeared to show a reduction of clonal diversity following treatment with selection of some clones with simpler copy number profiles. Conclusions: Both anastrozole and fulvestrant were effective and well-tolerated, enabling breast-conserving surgery in over 50% of patients. Clonal changes consistent with clonal selection by the treatment were seen in a subgroup of patients.
引用
收藏
页码:585 / 594
页数:10
相关论文
共 50 条
  • [1] Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
    Nathalie Quenel-Tueux
    Marc Debled
    Justine Rudewicz
    Gaetan MacGrogan
    Marina Pulido
    Louis Mauriac
    Florence Dalenc
    Thomas Bachelot
    Barbara Lortal
    Christelle Breton-Callu
    Nicolas Madranges
    Christine Tunon de Lara
    Marion Fournier
    Hervé Bonnefoi
    Hayssam Soueidan
    Macha Nikolski
    Audrey Gros
    Catherine Daly
    Henry Wood
    Pamela Rabbitts
    Richard Iggo
    British Journal of Cancer, 2015, 113 : 585 - 594
  • [2] First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis
    Liao, Weiting
    Huang, Jiaxing
    Wu, Qiuji
    Wen, Feng
    Zhang, Nan
    Zhou, Kexun
    Bai, Liangliang
    Li, Qiu
    BREAST CANCER, 2020, 27 (03) : 399 - 404
  • [3] First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis
    Weiting Liao
    Jiaxing Huang
    Qiuji Wu
    Feng Wen
    Nan Zhang
    Kexun Zhou
    Liangliang Bai
    Qiu Li
    Breast Cancer, 2020, 27 : 399 - 404
  • [4] Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
    Johnston, Stephen R. D.
    Kilburn, Lucy S.
    Ellis, Paul
    Dodwell, David
    Cameron, David
    Hayward, Larry
    Im, Young-Hyuck
    Braybrooke, Jeremy P.
    Brunt, A. Murray
    Cheung, Kwok-Leung
    Jyothirmayi, Rema
    Robinson, Anne
    Wardley, Andrew M.
    Wheatley, Duncan
    Howell, Anthony
    Coombes, Gill
    Sergenson, Nicole
    Sin, Hui-Jung
    Folkerd, Elizabeth
    Dowsett, Mitch
    Bliss, Judith M.
    LANCET ONCOLOGY, 2013, 14 (10): : 989 - 998
  • [5] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Benjamin Haaland
    Alberto J. Montero
    Gilberto Lopes
    Breast Cancer Research and Treatment, 2013, 138 : 961 - 965
  • [6] Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials
    Li, Meng
    Xiong, Yiting
    Liao, Chen
    He, Yunyan
    Duan, Sijia
    Yi, Fengming
    Wei, Yiping
    Zhang, Wenxiong
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 269 - 278
  • [7] Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
    Robertson, John F. R.
    Ferrero, Jean-Marc
    Bourgeois, Hugues
    Kennecke, Hagen
    de Boer, Richard H.
    Jacot, William
    McGreivy, Jesse
    Suzuki, Samuel
    Zhu, Min
    McCaffery, Ian
    Loh, Elwyn
    Gansert, Jennifer L.
    Kaufman, Peter A.
    LANCET ONCOLOGY, 2013, 14 (03): : 228 - 235
  • [8] Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis
    Wang, Jiayu
    Xu, Binghe
    Wang, Wenna
    Zhai, Xiaoyu
    Chen, Xuelian
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (03) : 535 - 544
  • [9] Randomized Phase 2 Neoadjuvant Trial Evaluating Anastrozole and Fulvestrant Efficacy for Postmenopausal, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Results of the UNICANCER CARMINA 02 French Trial (UCBG 0609)
    Lerebours, Florence
    Rivera, Sofia
    Mouret-Reynier, Marie-Ange
    Alran, Severine
    Venat-Bouvet, Laurence
    Kerbrat, Pierre
    Salmon, Remy
    Becette, Veronique
    Bourgier, Celine
    Cherel, Pascal
    Boussion, Veronique
    Balleyguier, Corinne
    Thibault, Fabienne
    Lavau-Denes, Sandrine
    Nabholz, Jean-Marc
    Sigel, Brigitte
    Trassard, Martine
    Mathieu, Marie-Christine
    Martin, Anne-Laure
    Lemonnier, Jerome
    Mouret-Fourme, Emmanuelle
    CANCER, 2016, 122 (19) : 3032 - 3040
  • [10] Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
    Fontein, Duveken B. Y.
    Charehbili, Ayoub
    Nortier, Johan W. R.
    Kranenbarg, Elma Meershoek-Klein
    Kroep, Judith R.
    Putter, H.
    van Riet, Yvonne
    Nieuwenhuijzen, Grard A. P.
    de Valk, Bart
    Terwogt, Jetske M. Meerum
    Algie, Gijs D.
    Liefers, Gerrit-Jan
    Linn, Sabine
    van de Velde, Cornelis J. H.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2190 - 2200